MODULEX-GRUPPEN
22.5.2024 18:36:27 CEST | Business Wire | Pressemeddelelse
Modulex Gruppen er glade for at kunne annoncere udnævnelsen af Mikkel Arreborg som Chief Finance og Operations Officer med base i koncernens hovedkvarter i Billund. Mikkel har en baggrund som CFO med en dokumenteret track record for strategisk finansielt lederskab og operationel ekspertise på tværs af forskellige brancher.
I løbet af sin tid som CFO hos Auto Solutions Group demonstrerede Mikkel enestående færdigheder i at styre finansielle operationer på tværs af et konglomerat af virksomheder. Hans ansvarsområder omfattede tilsyn med budgettering, finansiel rapportering og aktiv deltagelse i bestyrelsesmøder. Han stod især i spidsen for en omfattende omstrukturering af økonomiafdelingen og implementerede nye systemer og processer for at øge effektiviteten. Mikkel spillede en afgørende rolle i det succesfulde opkøb af Etac Bil i Norge, hvor han viste sin instrumentelle rolle i opkøb og integrationer.
"Det er mig en stor ære at blive en del af Modulex-teamet", siger Mikkel Arreborg. "Jeg er meget begejstret for at deltage i den spændende rejse, der ligger forude for koncernen, og den enestående mulighed for at lære af og bidrage til alle Modulex enheder på tværs af forskellige lande og kulturer."
Før han kom til Modulex Gruppen, havde Mikkel betydelige roller hos bl.a. PwC og BDO. Han har en kandidatgrad i revision og en diplomuddannelse i erhvervsøkonomi med speciale i regnskab og økonomistyring.
Ketil M. Staalesen, CEO i Modulex Gruppen, er begejstret for udnævnelsen af Mikkel og udtaler: "Jeg er virkelig begejstret for, at Mikkel har besluttet sig for at blive en del af vores team. Det er en meget vigtig rolle i fremtiden for den globale koncern, og det er en rolle, jeg arbejder meget tæt sammen med. Jeg var imponeret over Mikkels strategiske sans, hans umiddelbare observation af, hvordan han kunne gøre en forskel, og hans begejstring for at lære og lære alle forretningsenhederne at kende globalt."
Mikkel er en indflydelsesrig leder, der er forpligtet til at fremme et samarbejdsmiljø og bidrage til Modulex' formålsdrevne virksomhedskultur.
For mere information om Modulex, besøg vores hjemmeside https://modulex.com/ eller kontakt vores medierelationsteam på media@modulex.com
Om Modulex Gruppen:
Modulex blev grundlagt i 1963 af LEGO Koncernen og har siden 2009 været ejet af ledende partnere og eksterne investorer og er globalt førende inden for visuel kommunikation. Med rødder i dansk design excellence og et modulært skiltningskoncept har Modulex udviklet sin platform med design, wayfinding, skræddersyede løsninger og brandimplementeringer. I 2019 lancerede Modulex fabrikken i Billund, som er både ISO 9001 og 14001 certificeret, en bæredygtig produktlinje og blev tildelt Green Network-diplomet for 10. gang i træk. Den multinationale koncern har flere produktionsfaciliteter globalt. Koncernen er repræsenteret i over 300 byer i 45 lande.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240522566437/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
